← Leaderboards
Eric K Rowinsky
University Of Texas Hlth Sci Ctr San Ant
$9,623,858
Attributed
$9,623,858
Total exposure
24
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$9,623,858 · 24
By mechanism
M01$8,004,140 · 22
U01$1,616,449 · 1
R21$3,269 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Manjeri A Venkatachalam$6,261,879
- S Gail Eckhardt$7,082,740
- Anthony W Tolcher$2,350,887
- Chris H Takimoto$721,754
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectClinical Trial Phase INeoplasm /Cancer ChemotherapyDrug Screening /EvaluationPharmacokineticsAntineoplasticsDosageEnzyme InhibitorsDrug Adverse EffectInjection /InfusionNeoplastic ProcessDrug InteractionsNeoplastic GrowthThymidylate SynthaseCombination Cancer TherapyDrug Administration Rate /DurationAnalogCamptothecinIntravenous AdministrationPaclitaxelOral AdministrationAlkyltransferase
Grant awards (78)
Ph I Study Of BMS-247550 In PTS with advanced Neoplasms$16,264
M01 · FY2004 · RR
Phase II Pharmacologic/Biologic Study of Thalidomide$13,372
M01 · FY2004 · RR
Ph I Pharmacokinetics of NSC-655649/Cisplatin/G-CSF$11,566
M01 · FY2004 · RR
Phase I Clinical Trials of Anti-Cancer Agents$486,569
U01 · FY2003 · CA
ERBB1 AND ERBB2 BLOCKADE IN ADVANCED BREAST CANCER$3,269
R21 · FY2003 · CA
PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS$327,296
U01 · FY2002 · CA
SCH52365: PHASE I STUDY OF CYCLIC ORAL ADMINISTRATION$234,837
M01 · FY2002 · RR
PHASE I TRIAL OF BIZELESIN USING SINGLE BOLUS INFUSION EVERY 28 DAYS$234,837
M01 · FY2002 · RR
PHASE I TRIAL OF BIZELESIN USING SINGLE BOLUS INFUSION EVERY 28 DAYS$234,837
M01 · FY2002 · RR
PHASE I PHARMACOKINETIC STUDY OF BCH 4556$234,837
M01 · FY2002 · RR
PHASE I PHARMACOKINETIC STUDY OF BCH 4556$234,837
M01 · FY2002 · RR
PHASE I DOSE ESCALATION TRIAL OF ZENECA ZD9331$234,837
M01 · FY2002 · RR
PHASE I DOSE ESCALATION TRIAL OF ZENECA ZD9331$234,837
M01 · FY2002 · RR
7 DAY CONTINUOUS INFUSION OF L778123 IN RECURRENT MALIGNANCIES$234,837
M01 · FY2002 · RR
7 DAY CONTINUOUS INFUSION OF L778123 IN RECURRENT MALIGNANCIES$234,837
M01 · FY2002 · RR
PHASE I STUDY OF CCI 779 IN PATIENTS W/ ADVANCED SOLID TUMORS$234,837
M01 · FY2002 · RR
PHASE I STUDY OF CCI 779 IN PATIENTS W/ ADVANCED SOLID TUMORS$234,837
M01 · FY2002 · RR
TRIAL OF ZENECA ZD9331 GIVEN AS AN ORAL TABLET$234,837
M01 · FY2002 · RR
TRIAL OF ZENECA ZD9331 GIVEN AS AN ORAL TABLET$234,837
M01 · FY2002 · RR
PHASE I STUDY OF CP 358,774 IN SUBJECTS W/ ADVANCED SOLID TUMORS$234,837
M01 · FY2002 · RR
PHASE I STUDY OF CP 358,774 IN SUBJECTS W/ ADVANCED SOLID TUMORS$234,837
M01 · FY2002 · RR
PHASE I TRIAL OF LY231514 IN PATIENTS W/ VARYING DEGREES OF RENAL FUNCTION$234,837
M01 · FY2002 · RR
PHASE I TRIAL OF LY231514 IN PATIENTS W/ VARYING DEGREES OF RENAL FUNCTION$234,837
M01 · FY2002 · RR
PHASE I STUDY OF BMS 184476 IN PATIENTS W/ ADVANCED MALIGNANCIES$234,837
M01 · FY2002 · RR
PHASE I STUDY OF BMS 184476 IN PATIENTS W/ ADVANCED MALIGNANCIES$234,837
M01 · FY2002 · RR
PHASE I TRIAL OF LY231514 W/ IRINOTECAN$234,837
M01 · FY2002 · RR
PHASE I TRIAL OF LY231514 W/ IRINOTECAN$234,837
M01 · FY2002 · RR
SCH52365: PHASE I STUDY OF CYCLIC ORAL ADMINISTRATION$234,837
M01 · FY2002 · RR
COMBINATION PACLITAXEL/L778,123 IN SOLID TUMORS$0
M01 · FY2002 · RR
PHARMACOKINETIC STUDY OF TROXACITABINE AND CISPLATIN$0
M01 · FY2002 · RR
PHARMACOKINETIC STUDY OF TROXACITABINE AND CISPLATIN$0
M01 · FY2002 · RR
PHARMACOKINETIC TRIAL OF WEEKLY DOCETAXEL IN SOLID TUMOR$0
M01 · FY2002 · RR
PHARMACOKINETIC TRIAL OF WEEKLY DOCETAXEL IN SOLID TUMOR$0
M01 · FY2002 · RR
PHASE II TRIAL OF DX 8951F IN HEPATOCELLULAR CARCINOMA$0
M01 · FY2002 · RR
PHASE II TRIAL OF DX 8951F IN HEPATOCELLULAR CARCINOMA$0
M01 · FY2002 · RR
IV DX8951F IN PATIENTS WITH ADVANCED SOLID TUMORS$0
M01 · FY2002 · RR
IV DX8951F IN PATIENTS WITH ADVANCED SOLID TUMORS$0
M01 · FY2002 · RR
INTOPLICINE PHARMACOKINETICS--CONTINUOUS 5 DAY 4 WK DOSE$0
M01 · FY2002 · RR
INTOPLICINE PHARMACOKINETICS--CONTINUOUS 5 DAY 4 WK DOSE$0
M01 · FY2002 · RR
COMBINATION PACLITAXEL/L778,123 IN SOLID TUMORS$0
M01 · FY2002 · RR
PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS$378,781
U01 · FY2001 · CA
PHASE I STUDY OF CCI 779 IN PATIENTS W/ ADVANCED SOLID TUMORS$234,837
M01 · FY2001 · RR
7 DAY CONTINUOUS INFUSION OF L778123 IN RECURRENT MALIGNANCIES$234,837
M01 · FY2001 · RR
PHASE I DOSE ESCALATION TRIAL OF ZENECA ZD9331$234,837
M01 · FY2001 · RR
PHASE I PHARMACOKINETIC STUDY OF BCH 4556$234,837
M01 · FY2001 · RR
PHASE I TRIAL OF BIZELESIN USING SINGLE BOLUS INFUSION EVERY 28 DAYS$234,837
M01 · FY2001 · RR
PHASE I STUDY OF BMS 184476 IN PATIENTS W/ ADVANCED MALIGNANCIES$234,837
M01 · FY2001 · RR
SCH52365: PHASE I STUDY OF CYCLIC ORAL ADMINISTRATION$234,837
M01 · FY2001 · RR
PHASE I TRIAL OF LY231514 W/ IRINOTECAN$234,837
M01 · FY2001 · RR
PHASE I TRIAL OF LY231514 IN PATIENTS W/ VARYING DEGREES OF RENAL FUNCTION$234,837
M01 · FY2001 · RR
TRIAL OF ZENECA ZD9331 GIVEN AS AN ORAL TABLET$234,837
M01 · FY2001 · RR
PHASE I STUDY OF CP 358,774 IN SUBJECTS W/ ADVANCED SOLID TUMORS$234,837
M01 · FY2001 · RR
IV DX8951F IN PATIENTS WITH ADVANCED SOLID TUMORS$0
M01 · FY2001 · RR
PHARMACOKINETIC STUDY OF TROXACITABINE AND CISPLATIN$0
M01 · FY2001 · RR
PHARMACOKINETIC TRIAL OF WEEKLY DOCETAXEL IN SOLID TUMOR$0
M01 · FY2001 · RR
PHASE II TRIAL OF DX 8951F IN HEPATOCELLULAR CARCINOMA$0
M01 · FY2001 · RR
INTOPLICINE PHARMACOKINETICS--CONTINUOUS 5 DAY 4 WK DOSE$0
M01 · FY2001 · RR
COMBINATION PACLITAXEL/L778,123 IN SOLID TUMORS$0
M01 · FY2001 · RR
PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS$423,803
U01 · FY2000 · CA
PHASE I STUDY OF BMS 184476 IN PATIENTS W/ ADVANCED MALIGNANCIES$16,409
M01 · FY2000 · RR
PHASE I STUDY OF COMBINED 776C85 &5 FU TABLET &5 FU TABLETS$16,409
M01 · FY2000 · RR
PHASE I TRIAL OF LY231514 W/ IRINOTECAN$16,409
M01 · FY2000 · RR
SCH52365: PHASE I STUDY OF CYCLIC ORAL ADMINISTRATION$16,409
M01 · FY2000 · RR
PHASE I TRIAL OF LY231514 IN PATIENTS W/ VARYING DEGREES OF RENAL FUNCTION$16,409
M01 · FY2000 · RR
PHASE I STUDY OF CCI 779 IN PATIENTS W/ ADVANCED SOLID TUMORS$16,409
M01 · FY2000 · RR
TRIAL OF ZENECA ZD9331 GIVEN AS AN ORAL TABLET$16,409
M01 · FY2000 · RR
PHASE I STUDY OF IV DX88951F GIVEN DAILY FOR 5 DAYS EVERY 3 WEEKS$16,409
M01 · FY2000 · RR
PHASE I TRIAL OF BIZELESIN USING SINGLE BOLUS INFUSION EVERY 28 DAYS$16,409
M01 · FY2000 · RR
PHASE I PHARMACOKINETIC STUDY OF BCH 4556$16,409
M01 · FY2000 · RR
PHASE I DOSE ESCALATION TRIAL OF ZENECA ZD9331$16,409
M01 · FY2000 · RR
PHASE I STUDY OF CP 358,774 IN SUBJECTS W/ ADVANCED SOLID TUMORS$16,409
M01 · FY2000 · RR
7 DAY CONTINUOUS INFUSION OF L778123 IN RECURRENT MALIGNANCIES$16,409
M01 · FY2000 · RR
PHARMACOKINETIC TRIAL OF WEEKLY DOCETAXEL IN SOLID TUMOR$0
M01 · FY2000 · RR
PHASE II TRIAL OF DX 8951F IN HEPATOCELLULAR CARCINOMA$0
M01 · FY2000 · RR
IV DX8951F IN PATIENTS WITH ADVANCED SOLID TUMORS$0
M01 · FY2000 · RR
INTOPLICINE PHARMACOKINETICS--CONTINUOUS 5 DAY 4 WK DOSE$0
M01 · FY2000 · RR
COMBINATION PACLITAXEL/L778,123 IN SOLID TUMORS$0
M01 · FY2000 · RR
PHARMACOKINETIC STUDY OF TROXACITABINE AND CISPLATIN$0
M01 · FY2000 · RR